Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 8 od 16  
Back povratak na rezultate
2019, vol. 10, br. 2, str. 118-127
Dijabetesna nefropatija u tipu 2 dijabetesa - učestalost i faktori rizika
aUniverzitet u Istočnom Sarajevu, Medicinski fakultet, Foča, Republika Srpska, BiH + Univerzitetska bolnica Foča, Republika Srpska, BiH
bUniverzitet u Istočnom Sarajevu, Medicinski fakultet, Foča, Republika Srpska, BiH
cZdravstvena ustanova "Fresenius Medical Care", Centar za dijalizu, Šamac, Republika Srpska, Bosna i Hercegovina
dUniverzitet u Beogradu, Medicinski fakultet, Srbija

e-adresakovacevicvmarijana@gmail.com
Ključne reči: dijabetesna nefropatija; proteinurija; jačina glomerulske filtracija; faktori rizika
Sažetak
Uvod. Ciljevi rada su bili da se utvrdi učestalost i faktori rizika za dijabetesnu nefropatiju (DN) kod bolesnika sa tipom 2 dijabetesa i faktori povezani sa pogoršanjem funkcije bubrega tokom trogodišnjeg perioda. Metode. Studija je obuhvatila 81 bolesnika sa tipom 2 dijabetesa koji su na početku studije svrstani u dvije grupe: prva, 41 bolesnik sa DN (27 muškaraca, 62,03 ± 7,73 godina) i druga, 40 bolesnika bez DN (17 muškog pola, 61,73 ± 11,55 godina). Svim bolesnicima je uzeta anamneza, urađen objektivni pregled i laboratorijska ispitivanja. Na osnovu rezultata ispitivanja, poslije tri godine bolesnici obje grupe su podijeljeni u podgrupe sa nepromjenjenom funkcijom bubrega i podgrupe sa pogoršanjem funkcije definisanim kao povećanje proteinurija i/ili smanjenje jačine glomerulske filtracije (JGF) za više od 25%. Rezultati. Na početku ispitivanja zabilježena je visoka učestalost poznatih faktora rizika za dijabetes i DN kod obje grupe. Multivarijantna logistička analiza izdvojila je ženski pol i trajanje dijabetesa kao značajne prediktore DN. Nakon tri godine funkcija bubrega se pogoršala kod oko 50% bolesnika sa i bez DN, a u podgrupama sa pogoršanjem funkcije bubrega glikemija našte i HbA1c su bili statistički značajno veći nego u podgrupama sa stabilnom funkcijom bubrega. Linearna regresiona analiza je pokazala da je promjena JGF u trogodišnjem periodu značajno povezana sa starošću bolesnika, trajanjem dijabetesa, sistolnim krvnim pritiskom, razlikom u dijastolnom krvnom pritisku i proteinuriji. Promjena u proteinuriji značajno je povezana sa sistolnim krvnim pritiskom, razlikom u dijastolnom krvnom pritisku, kao i HbA1c i JGF na kraju studije. Zaključak. Kod bolesnika sa tipom 2 dijabetesa ženski pol i duže trajanje dijabetesa izdvojeni su kao značajni faktori rizika za DN, a starost bolesnika, trajanje dijabetesa, povišen krvni pritisak, loša glikoregulacija kao faktori rizika za pogoršanje funkcije bubrega.
Reference
*** (2013) KDOQI clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl, 3: 5-14
*** (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Summary and future directions. Diabetes Care, 37:44-9
Abejew, A.A., Belay, A.Z., Kerie, M.W. (2015) Diabetic complications among adult diabetic patients of a tertiary hospital in northeast Ethiopia. Advances in Public Health, 2015: 1-7
Advance Collaborative Group, Patel, A., Macmahon, S., Chalmers, J., Neal, B., Billot, L., et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 12;358(24):2560-72
American Diabetes Association (2018) Standards of medical care in diabetes. Diabetes Care, 41(1): 1-159
Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., Shahinfar, S., RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345(12): 861-9
de Zeeuw, D., Ramjit, D., Zhang, Z., Ribeiro, A.B., Kurokawa, K., Lash, J.P., Chan, J., Remuzzi, G., Brenner, B.M., Shahinfar, S. (2006) Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International, 69(9): 1675-1682
Đukanović, Lj. (2012) Prevencija dijabetesne nefropatije. Biomedicinska istraživanja, 3(2): 67-76
Earle, K.A., Porter, K.K., Ostberg, J., Yudkin, J.S. (2001) Variation in the progression of diabetic nephropathy according to racial origin. Nephrology Dialysis Transplantation, 16(2): 286-290
Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C., Bigger, J., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm, R.H. (2008) Effects of intensive glucose lowering in type 2 diabetes. New England journal of medicine, 358(24): 2545-59
Gilbert, M.P. (2015) Screening and treatment by the primary care provider of common diabetes complications. Medical Clinics of North America, 99(1): 201-219
GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet, 349(9069): 1857-1863
Hahr, A.J., Molitch, M.E. (2010) Diabetes, cardiovascular risk and nephropathy. Cardiology Clinics, 28(3): 467-475
Jager, K.J., van Dijk, P.C.W. (2007) Has the rise in the incidence of renal replacement therapy in developed countries come to an end?. Nephrology Dialysis Transplantation, 22(3): 678-680
Kovačević, M., Ristić, S., Lukić, L., Maksimović, Z., Marić, S., Vasilić, Z., Pavlović, D., Trifunović, D., Djukanović, L. (2013) Poređenje rezultata skrininga hronične bolesti bubrega u neendemskom i endemskom naselju. Biomedicinska istraživanja, 4(1): 26-32
Liang, S., Cai, G.Y., Chen, X.M. (2017) Clinical and pathological factors associated with progression of diabetic nephropathy. Nephrology, 22(4): 14-19
Ministarstvo zdravlja Republike Srbije, Republička stručna komisija za izradu i implementaciju vodiča dobre kliničke prakse (2013) Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje diabetes mellitus-a. Beograd: Agencija za akreditaciju zdravstvenih ustanova
Noubiap, J., Naidoo, J., Kengne, A.P. (2015) Diabetic nephropathy in Africa: A systematic review. World Journal of Diabetes, 6(5): 759-759
Resić, H., Mešić, E. (2015) Nadomještanje bubrežne funkcije u Bosni I Hercegiovini 2001-2014. Sarajevo: Institut za naučnoistraživački rad i razvoj UKCS, str. 42-50
Reutens, A.T., Atkins, R.C. (2011) Epidemiology of diabetic nephropathy. Contrib Nephrol, 170: 1-7
Ritz, E., Rychlik, I., Locatelli, F., Halimi, S. (1999) End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis, 34(5): 795-808
Rossing, P., Fioretto, P., Feldt-Rasmussen, B., Parv, H.-H. (2012) Diabetic nephropathy. u: Skorecki, K.; Chertow, G.M.; Marsden, P.A.; Taal M.W.; Yu A.S.L. [ur.] Brenner and rector's the kidney, Philadelphia, PA: Elsevier, 10th Edition, p. 1283-321
Ruggenenti, P., Fassi, A., Ilieva, A.P., Bruno, S., Iliev, I.P., Brusegan, V., i dr. (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 351(19): 1941-51
Sarafidis, P.A., Ruilope, L.M. (2014) Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: Time for re-evaluation?. Kidney International, 85(3): 536-546
Shichiń, M., Kishikawa, H., Ohkubo, Y., Wake, N. (2000) Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 23(Suppl 2): B21-9
Steiner, G. (2009) How can we improve the management of vascular risk in type 2 diabetes: Insights from field. Cardiovascular Drugs and Therapy, 23(5): 403-408
Tziomalos, K., Athyros, V.G. (2015) Diabetic nephropathy: New risk factors and improvements in diagnosis. Review of Diabetic Studies, 12(1-2): 110-118
U.S. Renal Data System (2009) USRDS 2009 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health
UK Prospective Diabetes Study Group (1994;11) UK prospective diabetes study. XII: Differences between Asian, afro-carribean and white caucasian type 2 diabetic patients at diagnosis of diabetes. Diabet Med, 11: 670-677
UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352(9131): 837-53
United States Renal Data System (2010;55) Annual data report: Atlas of chronic kidney disease and end stage renal disease in the United States: Incidence and prevalence. Am J Kidney Dis, 55:231-40
US Renal Data System (2008) USRDS 2008 annual data report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
van Buren, P.N., Toto, R. (2011) Hypertension in diabetic nephropathy: Epidemiology, mechanisms, and management. Advances in Chronic Kidney Disease, 18(1): 28-41
van Dijk, P.C.W., Jager, K.J., Stengel, B., Gronhagen-Riska, C., Feest, T.G., Douglas, B.J. (2005) Renal replacement therapy for diabetic end-stage renal disease: Data from 10 registries in Europe (1991-2000). Kidney International, 67(4): 1489-1499
Viswanathan, V., Tilak, P., Kumpatla, S. (2012) Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study. Indian J Med Res, 136: 46-53
 

O članku

jezik rada: srpski
vrsta rada: izvorni naučni članak
DOI: 10.7251/BII1902118K
primljen: 28.03.2019.
prihvaćen: 10.06.2019.
objavljen u SCIndeksu: 31.03.2021.

Povezani članci

Nema povezanih članaka